Physician profile
Catherine Ann Hoffman
NPI 1215908561
$1,504.76
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $231 · 2021: $22.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $290.75 | 2019-2020 | |
| Amgen INC. | $195.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $146.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $78.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $78.22 | 2019-2020 | |
| Lilly USA, LLC | $72.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.94 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $49.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.24 | 2019-2020 | |
| Pfizer INC. | $41.09 | 2019 | |
| Supernus Pharmaceuticals, INC. | $38.71 | 2019-2021 | |
| Rhodes Pharmaceuticals L.P. | $38.68 | 2019 | |
| Insulet Corporation | $33.46 | 2019 | |
| Csl Behring | $28.95 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $27.31 | 2019 | |
| Eisai INC. | $25.50 | 2019 | |
| Shire North American Group INC | $25.36 | 2019 | |
| Nevro Corp. | $22.92 | 2019 | |
| Abbott Laboratories | $22.71 | 2019 | |
| Masimo Corporation | $21.32 | 2019 | |
| Genentech USA, INC. | $16.48 | 2019 | |
| Adlon Therapeutics L.P. | $15.54 | 2019 | |
| Neos Therapeutics, LP | $15.18 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2019 | |
| Ibsa Pharma INC. | $14.53 | 2019 | |
| Sanofi Pasteur INC. | $13.75 | 2020 | |
| Seqirus USA INC | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.